Morning Overview on MSN

A Moderna mRNA flu shot won a unanimous FDA panel nod for older adults

Older adults who face the highest rates of flu hospitalization moved one step closer to a new vaccine option on June 18, 2026, when a federal advisory panel unanimously backed Moderna’s mRNA-based ...
Hosted on MSN

Moderna is up more than 70% in a month after a 9-0 FDA vote. Wall Street's average price target says it should fall 44%. What gives?

An FDA advisory panel voted 9-0 that Moderna's mRNA flu vaccine's benefits outweigh its risks. A final approval decision is expected by Aug. 5. The stock trades near a 52-week high, well above the ...
Seeking Alpha

Moderna: Flu Vaccine Progress Is Only Part Of The Story

MRNA received a unanimous advisory committee vote supporting mRNA-1010, its flu vaccine, for adults 50 and older. MRNA plans to launch mRNA-1010 for the 2026/2027 season, but is not guiding for a ...
24/7 Wall St

Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?

MRNA surged 14%, dwarfing the 2% gains of MRK and PFE, driven by an FDA flu vaccine endorsement and a blowout Q1 revenue beat. Despite MRNA's 130% YTD surge, Wall Street's consensus target of $43 sits ...

Sanofi sues Pfizer, Moderna over COVID shot technology

Sanofi has sued Pfizer and Moderna , alleging that their COVID-19 vaccines infringe several of the French pharmaceutical ...
AOL

Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?

Shares of Moderna (NASDAQ:MRNA) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a new 52-week high of $69.29.
STAT

Moderna co-founder Kenneth Chien on the future of mRNA — and Moderna

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Among all the awards and mementos Moderna ...
Morningstar

Moderna Is Applying MRNA Technology in Vaccines, but Also Cancer and Rare Disease Therapies

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...
Bloomberg L.P.

Moderna Upbeat on New Flu Shot to Help Educate Public About MRNA

Moderna Inc. Chief Executive Officer Stephane Bancel said he sees the pending launch of a planned flu vaccine as a chance to start a public conversation about how mRNA technology can offer better ...
Seeking Alpha

Moderna: From Buy To Sell After 128.2% Surge (Rating Downgrade)

Moderna, Inc. started 2026 on a high note and is now fluctuating around a resistance zone, +2σ band formed from the VWAP. One of the reasons for the bullish sentiment around MRNA over the past three ...
IFLScience

Review Of mRNA COVID Vaccines Once Again Finds They Are Safe, Highly Effective, And Full Of Promise

Tom has a Master's degree in Journalism. His editorial work covers anything from archaeology and the environment to technology and culture. Tom has a Master's degree in Journalism. His editorial work ...
The Motley Fool

Is Moderna Stock a No-Brainer Buy After a Key FDA Win?

On June 18, Moderna disclosed how a Food and Drug Administration (FDA) advisory committee voted unanimously that the benefits of its mRNA-based flu vaccine, mRNA-1010, outweigh the risks among ...